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Abstract: Traditional herbal (Kampo) medicines have been used since ancient times to treat patients with mental disorders. In the present 
report, we describe four patients with dysthymia successfully treated with Kampo medicines: Kamiuntanto (KUT). These four patients 
fulfilled the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for dysthymic disorder with easy   fatigability and 
sleeplessness, but did not fulfill the criteria for major depressive disorder. Treatment with KUT relieved depressive   status, fatigue and 
sleeplessness in these patients. As a result, their QOL (quality of life) was considerably improved. KUT may be useful as an additional 
or alternative treatment for dysthymia, especially in the field of primary health care.
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Introduction
Dysthymic disorder (dysthymia) is a disabling psy-
chiatric disorder characterized by mild but persistent 
depressive symptoms. In the USA, it is reported that 
the lifetime prevalence of dysthymia ranges from 3% 
to 6% in the general population,1,2 and up to 36% in 
psychiatric outpatient clinics.3 In Japan, a low life-
time prevalence (1.4%)4 and a 12-month prevalence 
of 0.7%5 for dysthymia have been reported. It has 
been  suggested  that  the  low  rate  of  dysthymia  in 
Japan is due to a lack of familiarity with operational 
diagnostic criteria, such as the Diagnostic and Sta-
tistical  Manual  of  Mental  Disorders  (DSM).  Early 
diagnosis  is  of  vital  important  for  the  successful 
treatment of dysthymia, especially in primary health 
care.   Additionally, about 25% of patients with dys-
thymia experience a chronic unchangeable status, and 
a subset of these patients develop major depressive 
disorder despite various treatments, such as antide-
pressants and   antianxiety drugs.
In  Japan,  traditional  herbal  (Kampo)  medicines 
(THM) are covered by national health insurance and 
play an important role in primary care, and several 
kampo  formulae  have  been  prescribed  for  mental 
disorders.6,7  THM  has  two  points  that  differ  from 
  Western Medicine, i) the Kampo formula is a crude 
drug, not a purified chemical product; ii) the diag-
nostic system in Kampo Medicine differs from that 
of Western  medicine. A  Kampo  formula  is  gener-
ally  composed  of  several  herbal  components  and 
is  generally  considered  safe.  Pseudoaldosteronism 
due to licorice root is a well known adverse effect 
of THM. There have also been allergic effects, such 
as skin eruption and liver injury, induced by crude 
drugs. Furthermore, it is crucial to understand that 
the  Kampo  diagnostic  system  is  constructed  from 
a paradigm that differs from the paradigm underly-
ing Western natural science. When we treat a patient 
with  dysthymia  using  Kampo  Medicine,  Kampo 
diagnosis is required in addition to that of Western 
Medicine. These characteristics make it difficult to 
perform controlled clinical trials. Therefore, there is 
no evidence supporting the use of Kampo formulae 
for dysthymia although Kampo formulae are often 
applied for mental disorders in Japan. However, it 
is a fact that there are responders to THM among 
patients with dysthimia. In this regard, we prescribed 
Kamiuntanto (KUT), one of these Kampo formulae, 
for the treatment of dysthymia with several physical 
and mental symptoms diagnosed by DSM-4th edition 
(DSM-IV).
Here, we describe four patients with dysthymia 
who were successfully treated with KUT.
case Reports
Treatment of each patient was approved under the 
comprehensive agreement of Gunma University. Info-
rmed consent was obtained from all four cases before 
treatment with Kampo therapy. Further, each patient 
was treated before 2008. The authors have received 
training  in  performing  clinical  trials  at  Gunma 
University.
case 1
A  63-year-old  male  consulted  the  Department  of 
Japanese  Oriental  (Kampo)  Medicine  (DJOM), 
Gunma University in October 200X requesting tra-
ditional  herbal  medicine  (Kampo)  for  dysthymic 
disorder  with  sleeplessness  and  malaise  that  had 
persisted for about 5 years despite treatment with 
antidepressants (Table 1). He worked at a bakery 
as  a  full-regular  employee  on  ordinary  days.  He 
was neither a smoker nor a drinker. At the initial 
examination,  there  were  no  remarkable  findings 
in  the  chest  or  abdomen,  and  hepato-renal  and 
thyroid functions appeared normal on both blood 
analysis and image diagnosis. Additionally, he had 
not complained of any clinical features indicating 
the dementia. He had been taking time off work 
several  days  a  month  due  to  fatigue.  Treatment 
with Kamikihito, one of the kampo formulae, for 
4 weeks failed to improve his symptoms. Kamiun-
tanto (KUT; Table 2) was therefore administered in 
addition to antidepressants. After KUT therapy for 
12 weeks, sleeplessness and malaise improved. The 
patient  was  accordingly  relieved  from  dysthymia 
and  estazolam  was  discontinued,  and  the  patient 
became able to commute every day. The improve-
ment in social activity has continued for 3 years 
with KUT. In addition, we evaluated the improve-
ment of depressive symptoms using global assess-
ment of functioning (GAF) scale by DSM-4th ed. 
Text revision ( DSM-IV TR )8 in all cases. Her GAF 
scale changed from 70–61 to 90–81.Herbal (Kampo) medicine for dysthymia
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case 2
A  62-year-old  female  consulted  DJOM  requesting 
Kampo  treatment  for  general  malaise  and  lack  of 
volition that had persisted for 2 years despite con-
ventional Western therapy, which consisted of ben-
zodiazepines. She was not regarded as having senile 
dementia. She was a housewife and barely able to 
perform  housework.  Her  status  was  diagnosed  as 
dysthymic disorder by operational diagnostic criteria; 
DSM-IV. Saikokeishikankyoto (decoction) therapy in 
addition to Western medicines for 4 months failed to 
improve her symptoms. Therefore, we changed the 
Kampo formula from Saikokeishikankyoto to KUT. 
Dysthymia, consisting of general malaise and depres-
sive symptoms was reduced by 80% after KUT ther-
apy for about 4 months, along with the occasional 
use of Kousosan (TJ-70, 2.5 g TSUMURA Co. Ltd 
Japan) to relieve her anxiety. Relief from dysthymia 
has continued for about 2 years with KUT treatment. 
Her GAF scale changed from 70–61 to 90–81.
case 3
A 61-year-old female developed a feeling of heavy 
head  and  sleeplessness  in  April  200X.  She  was 
receiving  atorvastatin  for  hyperlipidemia,  and  had 
also received a sleeping drug from a local hospital. 
However, her symptoms persisted, followed by the 
development of depressive symptoms and malaise, 
Table 2. Herbal components of Kamiuntanto (KUT).
Japanese  
name
english name Volume 
(gram)
Hange pinelliae Tuber 5.0
Bukuryo Hoelen 4.0
Chinpi Aurantii Nobilis pericarpium 3.0
Chikujo Banbusae Caulis 3.0
onji polygalae radix 2.0
Kanzo Glycyrrhizae radix 2.0
Genjin scrophulariae radix 2.0
Kijitsu Aurantii Fructus Immaturus 2.0
sansonin Zizyphi semen 2.0
Jiou rehmanniae radix 2.0
Taiso Zizyphi Fructus 2.0
Ninjin Ginseng radix 2.0
shokyo Zingiberis rhizoma 1.0
The herbs were mixed with 600 ml of water and boiled down to 300 ml, 
and the aqueous extract was filtered through a sieve. The extract, called 
a decoction, was administered twice a day before meals in the morning 
and evening.
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although  she  continued  to  work  as  a  pharmacist. 
She consulted our hospital requesting Kampo treat-
ment in November 200X + 2. She was diagnosed as 
having dysthymic disorder based on DSM-IV. Kou-
sosanryo (decoction) therapy for 8 weeks failed to 
improve dysthymia. Her symptoms relieved by 80% 
after 4 months of KUT administration, and thereafter 
she became able to concentrate on work and house-
keeping. Improvement of dysthymia has continued 
for 18 months with KUT treatment. Her GAF scale 
changed from 80–71 to 100–91.
case 4
A 53-year-old female (menopause: 51-year-old) came 
to DJOM requesting Kampo treatment for dysthymic 
disorder  with  sleeplessness,  malaise  and  nervous-
ness without vasomotor symptoms, consisting of hot 
flashes and sweating, which had persisted for about 
5 years. She was a housewife and barely performed 
housework. She had not been taking antidepressant 
therapy, although she was taking hypotensive drugs 
for  essential  hypertension.  Depressive  symptoms 
were relieved after 4 months of KUT treatment and 
the improvement continued for 6 months. However, 
sleeplessness,  easy  fatigability  and  appeteite  loss 
reappeared. Therefore, we changed KUT to another 
kampo  formula  (Kamikihito:  decoction)  and  have 
obtained  improvement  by  50%.  Her  GAF  scale 
changed from 70–61 to 90–81.
In all cases, there were no remarkable findings in 
the chest or abdomen, hepato-renal and thyroid func-
tions appeared normal on both blood analysis and 
image diagnosis, and dysthymic disorder had been 
diagnosed by a psychiatrist based on DSM-IV criteria. 
During the follow-up periods, there were no adverse 
reaction attributable to Kampo medicines.
Discussion
Dysthymia is defined in DSM-IV as follows: mild 
depressive  mood  continued  nearly  all  day  for  2 
years, and there were no major depressive episodes 
observed during at least the first 2 years. It has been 
reported  that  youth  are  susceptible  to  dysthymia, 
while elderly people demonstrate symptoms closer 
to  major  depressive  disorder.  Three  (No.  1.2.3  in 
Table 1) of our cases were elderly patients, however 
kampo treatment with KUT resulted in an improve-
ment  of  depressive  mood.  However,  one  of  the 
patients (No. 4 in Table 1.)   experienced dysthymic 
symptoms in the   postmenopausal period, and her sta-
tus was categorized as a climacteric mental disorder. 
It is well known that depressive symptoms in climac-
terium are associated with a decrease in estrogen (E2). 
Although an E2-like action of KUT has not been rec-
ognized, it is possible that KUT may also be effective 
for dysthymia in postmenopausal females.
Although  dysthymia  is  apt  to  be  regarded  as  a 
mild depressive disorder by non-psychiatrists, social 
loss due to dysthymia is serious. Cassano et al have 
reported  that  social  activity  shows  greater  reduc-
tion in patients with dysthymia than in patients with 
major  depressive  disorders.9  The  clinical  features 
of dysthymia are characterized by low ADL despite 
mild depressive symptom. The etiology of low ADL 
remains unclear, but it is possible that it may be diffi-
cult to diagnose dysthymia early because the depres-
sive  symptoms  are  mild.  In  addition,  the  physical 
symptoms such as general malaise as well as emo-
tional symptoms probably contribute to decreasing 
ADL  in  dysthymia.  The  clinical  characteristics  of 
each patient in this series are summarized in Table 1. 
Each patient complained of fatigue and sleeplessness. 
Furthermore, it is well known that dysthymia in cli-
macterium is characterized by severe malaise. KUT 
treatment resulted in the improvement of depressive 
status, as well as easy fatigability and sleeplessness, 
and so ADL would probably improve. These clinical 
courses suggest that KUT (Kampo medicine) may be 
useful as an additional or alternative treatment for 
dysthymia, especially in the field of primary health 
care.  During  this  period,  we  encountered  2  other 
patients with depressive symptoms, who did not fulfill 
the criteria for dysthymia because the period of mild 
depressive symptoms was less than 2 years. How-
evere, these patients were also successfully treated 
with KUT (data not shown). Kampo treatment gener-
ally aims not only at improving or regaining physical 
health, but also taking the patient’s psychic and emo-
tional imbalance into account.10 However, the efficacy 
is limited among responders to KUT treatement. To 
confirm this efficacy, further clinical trial such as N 
of 1 clinical study,11 will be required.
In Japan, traditional herbal medicines (Kampo) are 
covered by national health insurance, and are gener-
ally used in primary health care. KUT (kamiuntanto) 
is one of the kampo formulae used for the treatment Herbal (Kampo) medicine for dysthymia
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of mental disorders, such as insomnia or dementia.12 
Kampo formula is administered following traditional 
diagnosis, in addition to diagnosis by Western medi-
cine. The traditional target group for KUT comprises 
patients with sleeplessness, anxiety, and malaise after 
a serious illness as well as depressive status in patients 
lacking physical strength.9 Since patients with dysthy-
mia who complain of general malaise are close to the 
target group for KUT, we therefore treated 4 dysthy-
mia patients with KUT and achieved good outcomes. 
Further,  the  traditional  target  group  of  Kamikihito 
(a kampo formula), which was administered in case 
nos.  1  and  4,  comprises  patients  characterized  by 
appetite loss in addition to other symptoms.
It is still not clear whether KUT improves the sta-
tus of dysthymia, but several actions of KUT on the 
nervous system have been demonstrated. It has been 
reported that KUT potentiates the brain cholinergic 
system in an aged mouse model and its effect may 
be attributed to an increase in the activity of choline 
acetyltranseferase (ChAT).13 Those effects have also 
been demonstrated in thiamine-deficient mice that 
demonstrate impairment of learning and memory.14 
It has been considered that the beneficial effect of 
KUT  on Alzheimer’s  disease  (AD)  is  due  to  the 
potentiation of ChAT, but not inhibition of cholinest-
erase (ChE).12 Although an excess of HPA axis was 
observed in the patients with dysthymia, suppres-
sion of the HPA axis by KUT has not been demon-
strated. However, recently it has been reported that 
AD and depression are significant associated in the 
aging population, and interestingly ChAT polymor-
phism is significantly associated with depression.15 
Three of our patients were elderly, and KUT might 
improve dysthymic status through action on ChAT as 
in dementia. Furthermore, Smith et al have demon-
strated that cholinergic neurons were also decreased 
in  the  cerebral  cortex  such  as  the  frontal  lobe  in 
postmenopausal females, and estrogen replacement 
therapy  (ERT)  suppressed  the  decrease  in  cholin-
ergic neurons using SPECT and 123I-iodobenzovesa-
micol.16 Therefore, it is possible that KUT treatment 
may potentiate ChAT in the postmenopausal female. 
We consider that the dysthymic patient (Pt. no. 4 in 
Table  1)  in  climacterium  was  also  successfully 
treated with KUT due to its effects on ChAT. Thus, 
it is considered that KUT may be useful for various 
patients with dysthymia.
Finally,  we  present  4  patients  with  dysthymia 
  successfully treated with the Kampo formula: KUT. 
KUT may be useful and safe as an additional or alter-
native treatment for dysthymia. These observations 
encourage us to proceed further with controlled trials 
to confirm the efficacy of KUT.
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